Get all your news in one place.

100’s of premium titles.
One app.

Get all your news in one place.

100’s of premium titles. One news app.

The Latest Breaking News from FDA

Supreme Court to Consider Restrictions on Abortion Drug Mifepristone

The Supreme Court is reconsidering the accessibility of popular abortion drug, Mifepristone, a high-stakes case with potential electoral repercussions.

Top News

Read news from The Economist, FT, and more,
with one subscription

Safer eyedrops will require new FDA powers and resources, experts say

Repeated recalls of eyedrops are drawing new attention to the limited powers U.S. regulators have to oversee medical products made overseas

The Independent UK

Supreme Court to hear abortion pill case - Roll Call

The case is the first major Supreme Court abortion case since the landmark Dobbs v. Jackson Women’s Health Organization decision last year.

Roll Call

Here's What The FDA Approval Of Gene Editing For Sickle Cell Means For CRSP Stock And The Future Of Medicine

Biotech stocks could be at a major turning point after FDA approval of the first gene editing drug using Crispr technology. But gene editing therapies aren’t without risk, and questions remain about the safety and cost effectiveness of these experimental treatments.

Investors Business Daily

3 Solid Pharma Stocks for a Healthy Year-End Portfolio

The pharma industry is transforming due to the rapid adoption of AI and global healthcare spending, fostering innovation and patient care advancements. Therefore, fundamentally sound pharma stocks Eli Lilly (LLY), Wave Life Sciences (WVE) and Johnson & Johnson (JNJ) might be worth adding to boost your portfolio. Continue reading.

StockNews.com

3 Pharma Powerhouses to Boost Your Year-End Investments

Backed by an ever-growing need for chronic disease treatments, rapid investments in research and development, and widespread integration of technology, the pharmaceutical sector is anticipated to flourish. Thus, as we approach the end of 2023, three solid pharma stocks, GoodRx Holdings (GDRX), CytomX Therapeutics (CTMX), and Neurocrine Biosciences (NBIX), could…

StockNews.com

Up First briefing: Trump won't testify; FDA approves landmark gene-editing treatment

Donald Trump plans to skip testifying for a second time in the New York civil fraud trial. The FDA has approved the first-ever gene-editing treatment for a human disease.

WEKU

The Rwanda plan is failing – so watch as our cowardly government blames the civil service

Ministers are spending £290m of taxpayers’ money on a scheme that is yet to deliver. It’s our job as public servants to point out flaws in their plans, says Dave Penman, general secretary of the FDA union

The Guardian - UK

Get all your
news in one place.

100’s of premium titles.
One news app.

Salon

How to protect against emerging STIs

From gonorrhea and syphilis to newer ailments, these are the STDs that you need to be on the watch for

Android Central

Google could make the Pixel 8 Pro's thermometer a practical health feature

Code found in the Fitbit app suggests that it might soon be able to work with the Pixel 8 Pro's built-in thermometer.

The Hindu

US approves two gene therapies for sickle cell disease

The U.S. Food and Drug Administration on Friday approved a pair of gene therapies for sickle cell disease, including the first treatment based on the breakthrough CRISPR gene editing technology.

LiveScience

1st gene therapies for sickle cell cleared by FDA, including CRISPR treatment

The FDA approved two new therapies for sickle-cell disease, including the world's first-ever approved CRISPR therapy.

Get all your
news in one place.

100’s of premium titles.
One news app.

LiveScience

Widely used epilepsy drugs tied to rare, deadly side effect, FDA warns

The announcement comes after the FDA became aware of more than 40 cases of "DRESS syndrome" linked to the seizure medications levetiracetam and clobazam.

Investors Business Daily

Stock Market Rally Nears 2023 Highs; AMD, Google Jump On AI Push: Weekly Review

The stock market rally enjoyed modest weekly gains, with the major indexes all near 2023 highs. AMD and Google surged on AI news.

WEKU

FDA approves first gene-editing treatment for human illness

The Food and Drug Administration approved two genetic treatments for sickle cell disease, including one that uses gene-editing. The approvals offer hope for patients and signal a new medical era.

Bored Panda

“No Such Thing As Organic Honey”: 50 People Share Food Industry Secrets

Big money brings tough competition, and businesses can try all sorts of tactics to get an edge. The post “No Such Thing As Organic Honey”: 50 People Share Food Industry Secrets first appeared on Bored Panda.

Investors Business Daily

Crispr Stock Whipsaws Lower After FDA Approves Gene-Editing Treatment

Crispr stock crashed after FDA approved a groundbreaking gene-editing treatment. CRSP stock was last off around 11%.

The Independent UK

Lawmakers seek action against Elf Bar and other fruity e-cigarettes imported from China

House lawmakers are demanding information on federal efforts to stop the influx of kid-appealing electronic cigarettes from China

StockNews.com

3 Pharma Stocks Flashing 'Buy' Signals in December

The pharmaceutical industry is well-positioned for robust growth, driven by growing healthcare expenditure globally and the rapid adoption of digital technologies. Given the industry’s tailwinds, fundamentally strong pharma stocks, Collegium Pharmaceutical (COLL), Eton Pharmaceuticals (ETON), and GSK plc (GSK) could be ideal buys this month. Continue Reading….

1 … 83 84 85 86

People

From analysis to the latest developments in health,
read the most diverse news in one place.

Organisations

Advanced Micro Devices

441 stories

Read news from The Economist, FT, and more,
with one subscription

Topics

Places

Fourteen days free

Download the app

One app. One membership.
100+ trusted global sources.